Does Rallies show 13F holders for DNLI?

Yes. Rallies tracks hedge fund and 13F ownership data for DNLI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DNLI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DNLI. It does not provide personalized investment advice.

DNLI (Denali Therapeutics Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Denali Therapeutics Inc. Common Stock (DNLI) is a publicly traded Healthcare sector company. As of May 21, 2026, DNLI trades at $18.52 with a market cap of $2.92B and a P/E ratio of -6.34. DNLI moved +3.92% today. Year to date, DNLI is +17.54%; over the trailing twelve months it is +31.77%. Its 52-week range spans $10.57 to $33.33. Analyst consensus is strong buy with an average price target of $35.91. Rallies surfaces DNLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DNLI stock?

Hedge funds tracked by Rallies that own DNLI include Temasek Holdings, Polen Capital, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Denali Therapeutics Inc. Common Stock.

DNLI Key Metrics

Key financial metrics for DNLI
Metric	Value
Price	$18.52
Market Cap	$2.92B
P/E Ratio	-6.34
EPS	$-2.97
Dividend Yield	0.00%
52-Week High	$33.33
52-Week Low	$10.57
Volume	1
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-512.54M
Gross Margin	0.00%

Top Hedge Funds Holding DNLI

Temasek Holdings holds 7.01M shares of DNLI, changed +0.00% as of Mar 31, 2026.
Polen Capital holds 65.30K shares of DNLI, changed +142.75% as of Mar 31, 2026.
Eisler Capital holds 35.86K shares of DNLI, changed +4.01% as of Jun 30, 2024.

Latest DNLI News

Denali Therapeutics Secures Fast Track for Hunter Syndrome Drug with PDUFA April 2026 — Apr 1, 2026
FDA Extends Review Timeline for Denali's Tividenofusp Alfa MPS II Therapy Filing — Feb 10, 2026
Denali Therapeutics’ Brain-Penetrant ERT Cuts CSF Heparan Sulfate 91%, Eyes April 2026 PDUFA — Dec 30, 2025

Recent DNLI Insider Trades

Watts Ryan J. sold 35.20K (~$580.77K) on Jan 6, 2026.
Schuth Alexander O. sold 17.22K (~$284.10K) on Jan 6, 2026.
Ho Carole sold 806 (~$11.80K) on Aug 13, 2025.

DNLI Analyst Consensus

14 analysts cover DNLI: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.91.

Common questions about DNLI

Who owns DNLI stock?: Hedge funds tracked by Rallies that own DNLI include Temasek Holdings, Polen Capital, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Denali Therapeutics Inc. Common Stock.
Does Rallies show 13F holders for DNLI?: Yes. Rallies tracks hedge fund and 13F ownership data for DNLI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DNLI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DNLI. It does not provide personalized investment advice.